Patent ID: 7414026
Filing Date: 2008-08-19
Classification: A61K,A61P,C07K

Abstract:
1. A method of screening a compound for its ability to activate or suppress ABIN (A20-Binding Inhibitor of NF-κB activation) dependent NF-κB inhibition, said method comprising: a) combining a compound to be screened with a protein comprising ABIN amino acid consensus sequence of SEQ ID NO: 9 and having the ability to interact with protein A20, b) detecting an interaction between said compound and said protein, c) identifying compounds that interact with said protein, d) obtaining a cell line with that nucleic acid sequence encoding protein A20, nucleic acid sequence encoding said ABIN consensus sequence protein, and an NF-κB dependent reporter gene, e) administering at least one of TNF (tumor necrosis factor), IL-1 (interleukin-1), TPA (tissue plasminogen activator), TRADD (TNF receptor associated death domain), RIP (receptor interacting protein), TRAF2 (TNF receptor associated factor 2) to the cell line to induce activation of the NF-κB pathway, f) administering the detected compounds to said cell line, and g) determining if the administration of the detected compounds alter NF-κB dependent reporter gene expression, wherein an increase in expression indicates that the detected compounds suppress ABIN dependent NF-κB inhibition and a decrease in expression indicates that the compounds activate ABIN dependent NF-κB inhibition.